Last updated: July 10, 2026
Chlor-Trimeton is a legacy, small-molecule antihistamine product built around chlorpheniramine maleate. The financial trajectory is dominated by (1) generic substitution, (2) channel consolidation and rebate pressure, (3) limited near-term patent-driven pricing power in most markets, and (4) periodic demand swings driven by cold-and-allergy seasonality. In the U.S., the product’s revenue profile typically tracks OTC penetration, pharmacy mass-channel distribution, and competitive intensity from other oral antihistamines and generics, not novel clinical differentiation.
What is CHLOR-TRIMETON (chlorpheniramine maleate) and how is it used in the market?
Featured snippet: Chlor-Trimeton is an OTC oral antihistamine brand (active ingredient: chlorpheniramine maleate) used for symptoms of allergic rhinitis, hay fever, and other allergy-related conditions such as runny nose, sneezing, and itching.
Key product attributes that shape demand
- Therapeutic class: first-generation (sedating) H1 antihistamine.
- Core use case: acute allergy symptom relief and nonprescription treatment for common cold/allergy overlap symptom bundles in the OTC setting.
- Customer decision drivers: price, perceived “works for me” familiarity, dosing convenience, and sedation tolerance.
- Substitutability: high. Patients and prescribers in OTC contexts can switch between multiple antihistamines with similar indication positioning.
Form factor and regimen effects
- Revenue and volume typically correlate with the availability of common OTC dosage forms (tablets/capsules) and pack sizes that match pharmacy/club store merchandising.
- Sedation is a differentiator in both directions: it can be a selling point for nighttime use in some segments and a friction point for daytime use.
How has CHLOR-TRIMETON’s financial trajectory typically evolved as generics gained share?
Featured snippet: As chlorpheniramine maleate has matured into a generic commodity, brand economics generally compress as pricing converges toward generic benchmarks and retailers optimize toward lowest net cost.
Typical U.S. brand-to-generic compression pattern
- Phase 1: Brand-led penetration at launch and during early OTC adoption.
- Phase 2: Generic erosion after generic entry, with steady decline in brand net price supported only by merchandising and loyalty.
- Phase 3: Portfolio rationalization by wholesalers and retail buyers, with brand SKUs losing shelf space to generics and private labels.
- Phase 4: Stabilization at a lower base if the brand remains a recognized “default” within certain pharmacy trade channels or if pack formats remain competitively advantaged.
What drives year-to-year revenue volatility
- Allergy season timing: warmer springs can shift peaks earlier; late frosts can delay demand.
- Cold season overlap: winter respiratory seasons can expand the user base for antihistamine symptom relief.
- Promotional cycles: OTC antihistamine brands are exposed to periodic retailer promos and planogram changes.
What market dynamics pressure CHLOR-TRIMETON pricing and margins?
Featured snippet: Pricing and gross-to-net economics are constrained by generic substitution, rebate/fee structures across pharmacy and mass channels, and competitive antihistamine replacement by newer OTC options.
Structural margin headwinds
- Generic substitution: chlorpheniramine maleate’s identical active ingredient makes brand switching easy.
- Channel power: large pharmacy chains and mass retailers set terms that compress brand net pricing.
- Private label competition: retailers can offer lower-cost “store brand” antihistamines at similar efficacy.
- Formulation competition: other antihistamines (including less sedating options) compete for the same symptom set.
Competitive intensity beyond direct generic chlorpheniramine
- Second-generation antihistamines often win daytime usability positioning.
- Combination cold products can displace single-ingredient antihistamines in some symptom bundles.
- Nonpharmacologic and alternative OTCs (nasal sprays, decongestants, antihistamine nasal formulations) can siphon share in rhinitis subsegments.
How do FDA and OTC regulatory realities affect CHLOR-TRIMETON’s product economics?
Featured snippet: As an OTC antihistamine, chlorpheniramine maleate sits in a mature regulatory category with established labeling and manufacturing expectations, making regulatory change a low-frequency driver versus competitive and channel forces.
OTC regulatory factors impacting economics
- Labeling and consumer-facing claims constrain differentiation because safety and efficacy messaging must remain compliant.
- Manufacturing compliance affects cost base but is rarely a differentiator once products are established.
- Ingredient stability reduces technical execution risk for new entrants compared with biologics or complex specialty formats.
What patents protect CHLOR-TRIMETON, and when do they expire?
No patent estate analysis can be provided here because the prompt does not include:
- the exact U.S. NDA/ANDA or OTC listing identifiers, or
- the Orange Book entries (drug product and active ingredient) linked to the CHLOR-TRIMETON brand,
- nor the jurisdictions of interest.
Under strict requirements, a complete and accurate response is not possible without the specific patent and regulatory listing inputs needed to map expiration and exclusivity.
What generic entry risks exist for chlorpheniramine maleate brands like CHLOR-TRIMETON?
Featured snippet: For an OTC, commodity antihistamine, generic entry risk is structurally high but economically realized already in most markets where chlorpheniramine maleate is widely available as a generic.
Practical entry and share-taking mechanics
- Commodity manufacturing: process complexity is low compared with many modern dosage forms.
- Shelf replacement: generics compete at the point of sale via price, availability, and retailer placement.
- Formulation tolerance: substitution is common when the brand is not uniquely positioned by a protected formulation.
Likely scenarios for brand value erosion
- Net price compression: brand pricing drifts toward generic levels under retailer negotiations.
- Reduced distribution support: fewer promotional allowances reduce brand visibility.
- SKU rationalization: fewer pack sizes remain actively promoted.
How does CHLOR-TRIMETON compare with other OTC antihistamines on market dynamics?
Featured snippet: Chlor-Trimeton’s core competitive tradeoff is sedation versus daytime usability; newer antihistamines often compete for the “non-sedating” segment while chlorpheniramine retains a loyal subset.
Competitive comparison axes
- Sedation profile: first-generation antihistamines tend to be more sedating.
- Symptom coverage: overlaps heavily with other antihistamines for sneezing, itching, runny nose.
- Daytime usability: non-sedating options have an advantage for daytime allergy sufferers.
- Price: generics and private labels typically set the lower bound; brand premiums narrow as competition intensifies.
Commercial implication
Brand value typically persists only where distribution, habit, and pack economics support continued buyer preference despite lower-cost generics.
What does the competitive landscape look like for chlorpheniramine maleate?
Featured snippet: The landscape is dominated by low-cost manufacturers of the active ingredient and multiple OTC antihistamine substitutes within retail.
Competitive groups
- Generic chlorpheniramine maleate manufacturers
- OTC antihistamine brands with alternative actives (non-sedating positioning)
- Combination cold/cough and rhinitis products that include or substitute for antihistamine activity
- Private label antihistamines at scale
Buyer behavior patterns
- Pharmacy chains: optimize for lowest net cost per unit with acceptable customer satisfaction.
- Mass retailers and club stores: rely on price-led promotions and larger pack value.
- Online pharmacies and marketplaces: intensify price competition and reduce loyalty-based switching costs.
Where do revenues come from: channel mix and seasonality drivers?
Featured snippet: Antihistamine OTC revenues concentrate in seasonal allergy windows and are sensitive to retailer promotion cadence and shelf allocation.
Channel economics that matter
- Retail pharmacy: higher service levels and more frequent substitution, usually with negotiated net pricing.
- Mass and club: strong volume but promo-driven margins; private label can displace branded SKUs.
- E-commerce: price transparency can pull net price down, though it can also broaden access for niche loyalists.
Seasonality
- Allergy season defines spring and early summer peaks.
- Respiratory overlap can extend demand into colder months for symptomatic relief.
Key Takeaways
- Chlor-Trimeton’s market and financial trajectory are primarily driven by generic substitution, retail channel economics, and seasonal OTC demand.
- The product’s active ingredient, chlorpheniramine maleate, is a mature commodity, which generally limits brand pricing power and compresses margins over time.
- Competition extends beyond direct chlorpheniramine generics to other OTC antihistamines and combination cold products, with sedation profile shaping consumer preference.
- A complete patent and exclusivity timeline for CHLOR-TRIMETON cannot be produced without the specific Orange Book/active listing mapping for the brand and dosage form.
FAQs
- Why do first-generation antihistamines like chlorpheniramine maintain niche OTC demand despite generics?
- How do pharmacy rebate structures typically affect OTC antihistamine brand net pricing versus generics?
- What drives substitution from chlorpheniramine to non-sedating antihistamines in allergy patients?
- How does pack size strategy influence OTC revenue performance for commodity antihistamines?
- What retail promotion patterns most affect year-to-year volume for OTC allergy symptom brands?
References
No sources cited.
